| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by financing activities | -3,787 | 856 |
| Effect of exchange rate on cash and cash equivalents | 0 | 0 |
| Net decrease in cash and cash equivalents | -24,526 | -7,764 |
| Cash and cash equivalents at beginning of period | 89,423 | - |
| Cash and cash equivalents at end of period | 64,897 | - |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)